| Field | Specification |
|---|---|
| Target | |
| Alternative names | Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1; Inositol polyphosphate-5-phosphatase D; Inositol polyphosphate-5-phosphatase of 145 kDa; SIP-145; Phosphatidylinositol 4,5-bisphosphate 5-phosphatase; SH2 domain-containing inositol 5'-phosphatase 1; SH2 domain-containing inositol phosphatase 1; SHIP-1; p150Ship; hp51CN; INPP5D; SHIP; SHIP1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human INPP5D recombinant protein (Position: Q81-E1093). Human INPP5D shares 87.6% and 87.5% amino acid (aa) sequence identity with mouse and rat INPP5D, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (gene INPP5D) in human samples and is validated for Western blot, flow cytometry and ELISA. The predicted molecular weight is 133.3 kDa, and the supplier reports an observed band at about 145 kDa.
SHIP1 (encoded by INPP5D) is an SH2 domain-containing inositol 5-phosphatase expressed mainly in blood cells. It converts PI(3,4,5)P3 to PI(3,4)P2, acting as a negative regulator of PI3K signaling downstream of immune receptors. SHIP1 limits activation of B cells, mast cells and myeloid cells and is studied in immunology and microglial biology.
| Target | Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 (gene INPP5D; UniProt Q92835, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 133.3 kDa |
| Observed MW | 145 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.25 µg/mL (Human) |
|---|---|
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human Raji cells, human THP-1 cells, human K562 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.25 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with a confirmed signal (flow cytometry): THP-1 cells.
Immunogen
Recombinant human INPP5D fragment (Gln81–Glu1093), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 87.6% and 87.5%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 1 in the cytoplasm, cell membrane, membrane raft and membrane. Tissue expression noted by UniProt (human): Specifically expressed in immune and hematopoietic cells. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
